LAUSR

Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.

Sign Up to like & get
recommendations!
0 Published in 2021 at "Toxicology and applied pharmacology"

DOI: 10.1016/j.taap.2021.115797

Abstract: Dabrafenib is a BRAF inhibitor used in combination treatment of malignant melanoma and non-small cell lung carcinoma. In this study, we aimed to characterize its interactions with cytochrome P450 (CYP) isoenzymes and ATP-binding cassette (ABC)… read more here.

Keywords: combination; inhibits abcg2; dabrafenib inhibits; dabrafenib ... See more keywords